Mumbai, India – February 2025 – ImmunoACT, the pioneering IIT Bombay-incubated cell and gene therapy company, marked a historic moment at the Emerging Science, Technology & Innovation Conclave (ESTIC 2025), where Honourable Prime Minister Narendra Modi was presented with NexCAR19® – the world’s first humanised CAR-T therapy developed entirely in India.
Developed with support from the Department of Biotechnology (DBT) and BIRAC, NexCAR19® delivers comparable efficacy to global CAR-T therapies at nearly one-tenth the cost, treating Acute Lymphocytic Leukemia and other challenging cancers. In a short span, it has reached 500 patients, proving India’s capability to scale advanced, accessible cell therapies without compromising safety or rigor. Building on this success, ImmunoACT is launching the HOPE Initiative – an end-to-end ecosystem for patient support.
“This proud moment underscores India’s Atmanirbhar vision and path to Viksit Bharat,” said Dr. Rahul Purwar, Founder & CEO of ImmunoACT. “NexCAR19® exemplifies how Indian innovation can deliver life-saving treatments affordably for the world, and we’re committed to expanding access through initiatives like HOPE.”
At ESTIC 2025, Dr. Jitendra Singh, Minister of Science & Technology and Earth Sciences, showcased Talicabtagene autoleucel alongside two quantum technologies, highlighting India’s biotech leadership. Under DBT’s BioE3 Policy, ImmunoACT is scaling a 200L GMP platform to treat up to 1,000 patients annually.
About ImmunoACT ImmunoACT is a clinical-stage biotech company focused on affordable CAR-T therapies, with NexCAR19® as India’s first approved indigenous CAR-T (CDSCO-authorized). From IIT Bombay roots via SINE and BIRAC’s BioNest, it advances treatments for blood cancers, solid tumours, and beyond. Visit: www.immunoact.com
Media Contact: helpdesk@immunoact.com